SCHEMBL5748483

SCHEMBL5748483

COc1c(-c2ccccc2)cc(C(=O)Nc2c(Cl)cncc2Cl)c2c3cc(N)ccc3n(C)c12

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 19/20 0.43
▸ PDE4D Q08499 9/20 0.43
▸ PDE4A P27815 8/20 0.42
▸ PDE4C Q08493 8/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5737268 0.87 PDE4B (0.43) PDE4BPDE4DPDE4APDE4C
SCHEMBL5748929 0.86 PDE4B (0.41) PDE4BPDE4DPDE4APDE4C
SCHEMBL4027963 0.82 PDE4D (0.56) PDE4BPDE4DPDE4APDE4C
SCHEMBL5016450 0.72 PDE4D (0.57) PDE4BPDE4DPDE4APDE4C
SCHEMBL5016433 0.72 PDE4D (0.58) PDE4BPDE4DPDE4APDE4C
SCHEMBL4026393 0.70 PDE4D (0.55) PDE4BPDE4DPDE4APDE4C
SCHEMBL4028106 0.68 PDE4D (0.52) PDE4BPDE4DPDE4APDE4C
SCHEMBL4026379 0.68 PDE4D (0.52) PDE4BPDE4DPDE4APDE4C
SCHEMBL4032068 0.68 PDE4D (0.57) PDE4BPDE4DPDE4APDE4C
SCHEMBL13777262 0.67 PDE4B (0.51) PDE4BPDE4DPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620429-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Glenmark Pharmaceuticals S.A. (CH) 2006-02-01 — — EP disclosed
WO-2004089940-A1 NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (US) 2004-10-21 — — WO disclosed
Send feedback